Rosenman Marc B, Mahon Barbara E, Downs Stephen M, Kleiman Martin B
Section of Children's Health Services Research, Regenstrief Institute, Indiana University School of Medicine, 1050 Wishard Boulevard, Indianapolis, IN 46202, USA.
Arch Pediatr Adolesc Med. 2003 Jun;157(6):565-71. doi: 10.1001/archpedi.157.6.565.
Chlamydia trachomatis exposure at birth may cause conjunctivitis or pneumonia. Until recently, a course of oral erythromycin prophylaxis was recommended for C trachomatis-exposed neonates. However, recognition of an association between erythromycin and pyloric stenosis prompted a change to a watchful waiting recommendation under which only infants who develop symptomatic C trachomatis infection are treated with oral erythromycin.
To compare erythromycin prophylaxis with watchful waiting for a hypothetical cohort of 100 000 neonates exposed to C trachomatis.
In a decision tree, potential outcomes were C trachomatis conjunctivitis, C trachomatis pneumonia (which could require inpatient or outpatient therapy), no clinical disease, and pyloric stenosis. Published data were reviewed to derive probability point estimates and ranges. Estimated charges served as outcome measures.
Watchful waiting is less expensive than erythromycin prophylaxis ($15.1 million vs $28.3 million); prophylaxis prevents 5986 cases of C trachomatis pneumonia, including 1197 hospital admissions, but causes 3284 pyloric stenosis cases. (For every 30 infants given oral erythromycin prophylaxis, one additional case of pyloric stenosis would be expected to occur, and approximately 1.8 cases of C trachomatis pneumonia would be prevented.) In sensitivity analyses, if more than 3.4% of exposed neonates are hospitalized for C trachomatis pneumonia, prophylaxis becomes favored.
This study supports the watchful waiting recommendation for asymptomatic C trachomatis-exposed neonates. However, there are wide plausible ranges for pyloric stenosis risk after erythromycin administration and for the incidence of C trachomatis pneumonia severe enough to require hospitalization; under some combinations of these rates, prophylaxis could be favored.
新生儿出生时暴露于沙眼衣原体可能会导致结膜炎或肺炎。直到最近,对于暴露于沙眼衣原体的新生儿,推荐口服红霉素进行预防治疗。然而,由于认识到红霉素与幽门狭窄之间的关联,现在改为采用观察等待的建议,即仅对出现沙眼衣原体感染症状的婴儿使用口服红霉素进行治疗。
比较红霉素预防治疗与观察等待策略对假设的10万名暴露于沙眼衣原体的新生儿的效果。
在决策树中,潜在结果包括沙眼衣原体结膜炎、沙眼衣原体肺炎(可能需要住院或门诊治疗)、无临床疾病以及幽门狭窄。查阅已发表的数据以得出概率点估计值和范围。估计费用作为结果指标。
观察等待的费用低于红霉素预防治疗(1510万美元对2830万美元);预防治疗可预防5986例沙眼衣原体肺炎,包括1197例住院治疗,但会导致3284例幽门狭窄病例。(每给30名婴儿进行口服红霉素预防治疗,预计会额外出现1例幽门狭窄病例,同时可预防约1.8例沙眼衣原体肺炎。)在敏感性分析中,如果超过3.4%的暴露新生儿因沙眼衣原体肺炎住院,预防治疗则更具优势。
本研究支持对无症状的暴露于沙眼衣原体的新生儿采用观察等待的建议。然而,服用红霉素后发生幽门狭窄风险以及严重到需要住院的沙眼衣原体肺炎发病率的合理范围较宽;在这些发生率的某些组合情况下,预防治疗可能更具优势。